ArticleCancer2018
Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.
Article in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Exploring marine-derived compounds as potential anti-cancer agents: Mechanisms and therapeutic implications.Cancer pathogenesis and therapy · 2026Review
- The global epidemiology of acute myeloid leukaemia.Nature reviews. Clinical oncology · 2026Review
- Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers.The oncologist · 2025Article
- Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.Haematologica · 2025Article
- Current status and research directions in acute myeloid leukemia.Blood cancer journal · 2024Review
- Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia.Journal of the National Cancer Institute · 2024Article
- Travel-time barriers to specialized cancer care for adolescents and young adults with acute lymphoblastic leukemia.JNCI cancer spectrum · 2024Article
- Association between Serum Lactate Dehydrogenase Level and 30-day Mortality in Patients with Intracranial Hemorrhage with Acute Leukemia in the Induction Phase: A Cohort Study.Global medical genetics · 2024Article
- The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients.Annals of hematology · 2024Article
- Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.Clinical hematology international · 2024Article
- Disparities in treatment and survival in early-stage hepatocellular carcinoma in California.Journal of surgical oncology · 2023Article
- Early mortality after chemotherapy as a quality indicator-the leukemia perspective.Blood cancer journal · 2023Article
- Demographic disparities in receipt of care at a comprehensive cancer center.Cancer medicine · 2023Article
- Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.Cancer · 2023Article
- Recent Advances in the Treatment and Supportive Care of POEMS Syndrome.Journal of clinical medicine · 2022Review
- Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study.BMC cancer · 2022Article
- Improved survival in cervical cancer patients receiving care at National Cancer Institute-designated cancer centers.Cancer · 2022Article
- ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.Annals of hematology · 2022Article
- Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States.Blood advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo the authors' knowledge, few population-based studies to date have evaluated the association between location of care, complications with induction therapy, and early mortality in patients with acute myeloid leukemia (AML).
methodsUsing linked data from the California Cancer Registry and Patient Discharge Dataset (1999-2014), the authors identified adult (aged ≥18 years) patients with AML who received inpatient treatment within 30 days of diagnosis. A propensity score was created for treatment at a National Cancer Institute-designated cancer center (NCI-CC). Inverse probability-weighted, multivariable logistic regression models were used to determine associations between location of care, complications, and early mortality (death ≤60 days from diagnosis).
resultsOf the 7007 patients with AML, 1762 (25%) were treated at an NCI-CC. Patients with AML who were treated at NCI-CCs were more likely to be aged ≤65 years, live in higher socioeconomic status neighborhoods, have fewer comorbidities, and have public health insurance. Patients treated at NCI-CCs had higher rates of renal failure (23% vs 20%; P = .010) and lower rates of respiratory failure (11% vs 14%; P = .003) and cardiac arrest (1% vs 2%; P = .014). After adjustment for baseline characteristics, treatment at an NCI-CC was associated with lower early mortality (odds ratio, 0.46; 95% confidence interval, 0.38-0.57). The impact of complications on early mortality did not differ by location of care except for higher early mortality noted among patients with respiratory failure treated at non-NCI-CCs.
conclusionsThe initial treatment of adult patients with AML at NCI-CCs is associated with a 53% reduction in the odds of early mortality compared with treatment at non-NCI-CCs. Lower early mortality may result from differences in hospital or provider experience and supportive care. Cancer 2018;124:1938-45. © 2018 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.